Janet Woodcock (AP Images)
Advocacy groups don't want Janet Woodcock to head the FDA, blasting ‘regulatory failures’ in opioid crisis
It turns out the controversies around Janet Woodcock’s regulatory legacy weren’t limited to Sarepta’s eteplirsen.
A coalition of advocacy groups dedicated to the opioid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
